InsiderTrades

Form 4 for KYMR Kymera Therapeutics, Inc.

Accepted 2026-06-22 17:47:25 ET · period of report 2026-06-22 · accession 0001193125-26-277766 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-06-22 17:47 2026-06-22 KYMR Goodman Noah Chief Business Off M - OptEx $21.05 +2,500 52.7K +5% +$52.6K
DT 2026-06-22 17:47 2026-06-22 KYMR Goodman Noah Chief Business Off S - Sale+OE $99.00 -2,500 50.2K -5% -$247.5K
DT 2026-06-22 17:47 2026-06-22 KYMR Goodman Noah Chief Business Off M - OptEx $0.00 -2,500 95.0K -3% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-22 M A 2,500 $21.05 52,695.44 D — — (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
2 Common Common Stock 2026-06-22 S D 2,500 $99.00 50,195.44 D — — (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
3 Derivative Stock Option (Right to Buy) 2026-06-22 M D 2,500 $0.00 95,000 D $21.05 · — to 2035-04-07 2,500 Common Stock (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. (F2) Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.